Anti-nuclear Antibody (ANA) Testing Market information, by type (immunofluorescence, enzymelinked, immunosorbent assay (ELISA) and others), by application (Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Polymyositis, Scleroderma, Sjögren's syndrome, and others), by End User (Hospitals and clinics, research laboratories, and others) - Forecast to 2027

Market Synopsis of Anti-nuclear Antibody (ANA) Testing Market:

Anti-nuclear Antibody (ANA) Test is used to detect antinuclear antibodies in blood. Immune system makes antibodies to fight with various infections. Antinuclear antibodies often attack on own tissues. ANA test helps to determine autoimmune diseases like rheumatoid arthritis and lupus. Increasing technological advancements, adoption of new techniques and increasing prevalence of various autoimmune diseases are driving the growth for anti-nuclear antibody (ANA) testing market. Major brands are investing money in R&D to develop more advanced product for the market that is another key driver for the market.

The Anti-nuclear Antibody (ANA) testing market is growing at the CAGR of ~9.6% during the forecast period and expected to reach US$ 1300.6 million by 2023.

Key Players for Anti-nuclear Antibody (ANA) Testing Market:     

Some of the key players in this market are: Abcam plc. (US), Alere (US), Antibodies Inc.(US), Bio-Rad Laboratories, Inc. (US), Erba Diagnostics (US), Indur Services, Inc. (US), MBL INTERNATIONAL (US), Merck KGaA (Germany), Trinity Biotech (Republic of Ireland)

Intended Audience

• Anti-nuclear Antibody (ANA) Test products manufacturers


• Anti-nuclear Antibody (ANA) Test products and services providers


• Medical Research laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors

Market Segments:      

Anti-nuclear Antibody (ANA) Testing Market has been segmented on the basis of type which comprise immunofluorescence (Primary or direct and Secondary or indirect), enzymelinked, immunosorbent assay (ELISA) (Direct ELISA, Indirect ELISA, Sandwich ELISA, Competition/Inhibition ELISA), and others. On the basis of application, it segmented into Rheumatoid arthritis (Seropositive, Seronegative), Systemic lupus erythematosus (SLE) (Discoid lupus erythematosus, Subacute cutaneous lupus erythematosus, Neonatal lupus), Polymyositis, Scleroderma (localized scleroderma, systemic scleroderma), Sjögren's syndrome (Primary, secondary) , and others. On the basis of end user, it segmented into Hospitals and clinics, research laboratories, and others.

FIGURE 1                   ANTI-NUCLEAR ANTIBODY (ANA) TESTING MARKET SHARE, BY APPLICATION (%)

Study objectives of Anti-nuclear Antibody (ANA) Testing Market:

• To provide detailed analysis of the Anti-nuclear Antibody (ANA) Testing market structure with historical and forecast revenue for the next 7 years of the various segments and sub-segments of the Anti-nuclear Antibody (ANA) Testing Market


• To provide insights about the key drivers, restraints, opportunities and challenges that affecting the growth of the Anti-nuclear Antibody (ANA) Testing market


• To provide analysis of the market with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.


• To provide detail analysis of the market that segmented on the basis of type, by application, by end user, and its sub-segments.


• To provide detail analysis of Anti-nuclear Antibody (ANA) testing market mainly based on value chain analysis, Porter’s five forces, Price analysis, and Supply Chain analysis etc.


• To provide detail country level analysis of the market with respect to the current market size and future prospective


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Anti-nuclear Antibody (ANA) Testing Market


• To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Anti-nuclear Antibody (ANA) Testing market

Regional Analysis of Anti-nuclear Antibody (ANA) Testing Market:               

Considering the global scenario of the market, North America is largest market for Anti-nuclear Antibody (ANA) Testing, in North America region US hold largest market share while European market is second largest, and especially the growth rate is higher in west European countries. On the other hand, Asia-Pacific (APAC) is fastest growing market and expected to grow significantly during the forecast period. Middle East and Africa (ME&A) is likely to have a limited growth in the market due to less awareness of devices and treatment.

Anti-nuclear Antibody (ANA) Testing Market, by Region

• Americas




• North America




• US


• Canada




• Latin America




• Europe




• Western Europe




• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe




• Eastern Europe




• Asia-Pacific




• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific




• The Middle East & Africa




• Middle East


• Africa

Research Methodology:

 Sources: Directorate of Industries, Annual report, White paper, Company Presentation

The report for Anti-nuclear Antibody (ANA) Testing Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :